Table 2.

Parameters of cardiac outcome/function during ICU stay

	COVID‐19 (n = 76)		Non‐COVID‐19 (n = 76)
Parameter	n	Median (Q3–Q1) or %	n	Median (Q3–Q1) or %	P value
Myocardial injury	57/73	78.1%	54/56	96.4%	0.004*
Cardiac laboratory markers
Initial hs‐Tn (%)	73	178.6 (481.1)	56	317.9 (398.2)	0.003*
Max. hs‐Tn (%)	73	354.3 (1409.6)	56	550.0 (1108.9)	0.021*
Initial CK (U/L)	74	174.5 (320.8)	76	103.0 (350.8)	0.231
Max. CK (U/L)	74	518.0 (856.3)	76	490.5 (949.0)	0.864
Initial CK‐MB (U/L)	44	19.1 (16.6)	51	27.3 (26.2)	0.001*
Max. CK‐MB (U/L)	44	22.0 (28.8)	51	38.0 (42.0)	0.002*
Initial NT‐proBNP (pg/mL)	44	811.0 (2849.8)	56	3890.0 (6926.3)	<0.001*
Max. NT‐proBNP (pg/mL)	44	2217.1 (4481.3)	56	6625.5 (13920.0)	0.001*
Functional parameters on TTE	48/76	63.2%	72/76	94.7%
Reduced LVEF	14/48	29.2%	18/72	25.0%	0.676
Newly onset of reduced LVEF	10/48	20.8%	9/72	12.5%	0.307
LVEF (%)	48	55.0 (10.0)	72	55.0(8.8)	0.277
LV dilatation	1/44	2.3%	2/66	3.0%	>0.999
RV dilatation	10/44	22.7%	11/68	16.2%	0.460
Pericardial effusion	3/47	6.4%	8/71	11.3%	0.522
Radiology findings
Cardiomegaly	35/76	46.1%	35/76	46.1%	>0.999
Cardiomegaly during FU	15/76	19.7%	13/76	17.1%	0.835
Pulmonary venous congestion	26/76	34.2%	56/76	73.7%	<0.001*

CK, creatine kinase; CK‐MB, creatine kinase myoglobin fraction; FU, follow‐up; hs‐Tn, high‐sensitive troponin; initial, first obtained value; LV, left ventricular; LVEF, left ventricular ejection fraction; Max., highest level of cardiac biomarker obtained during the total period of the ICU stay; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide, RV, right ventricular, TTE, transthoracic echocardiography.

Cardiac outcome of patients during intensive care unit (ICU) stay.

^* P < 0.05.